CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 127 enrolled
Drug / intervention
Zolpidem extended-release +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01685073
NCT01685073Phase 3Completed

The Role of Sleep in the Treatment of Cannabis Use Disorders

Johns Hopkins University·interventional·Posted Sep 13, 2012·Updated May 22, 2019

In Brief

A Phase 3 clinical trial evaluating Zolpidem extended-release and MET/CBT for Drug Addiction. Completed, enrolled 127 participants across 1 site.

Detailed Summary

The number of people seeking treatment for marijuana-related problems is on the rise, yet there is no currently accepted medication proven to help them quit. Frequent marijuana users have reported that they have trouble sleeping when they try to quit, and that the loss of sleep can lead to relapse. This research is designed to measure the severity of sleep problems in people as they are trying to quit heavy use of marijuana, and to investigate whether extended-release zolpidem (Ambien CR®) can improve quit rates among people trying to stop using marijuana.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug Addiction
CountriesUnited States

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 13, 2012
Enrollment StartSep 1, 2012
Primary CompletionJul 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 13.8 years ago

Interventions

Zolpidem extended-releasedrug

nightly administration of zolpidem extended-release

MET/CBTbehavioral

a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants